- DARZALEX® is not chemotherapy. DARZALEX® is a monoclonal antibody that works with your immune system. Monoclonal antibodies work by attaching themselves to multiple myeloma cells in your body and directly killing them, and/or signaling your immune system to destroy them
- DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells
The main goal of the study was to measure the length of time patients live without their multiple myeloma getting worse or their passing away from any cause
- Another goal was to measure response rate, which is the percentage of patients who responded to treatment. Talk to your doctor about how response is measured
The majority of patients responded to the following DARZALEX® combination treatments:
DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
- 9 out of 10 patients responded to DARZALEX® + Rd vs 7 out of 10 with Rd alone
DARZALEX® was studied in combination with Velcade® and dexamethasone (Vd) vs Vd alone in 498 patients who had received a minimum of 1 prior treatment
- Almost 8 out of 10 patients responded to DARZALEX® + Vd vs almost 6 out of 10 with Vd alone
- DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
- DARZALEX® combination treatments reduced patients’ risk of their disease getting worse or their passing away from any cause by more than 60%
Click here if you are a healthcare professional.
Revlimid® is a registered trademark of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.
Depending on a variety of factors such as how many prior therapies you’ve received, your health status, and/or the stage of your multiple myeloma, your doctor may consider the following treatment options:
Multiple Myeloma Drug Therapies
- Immunomodulatory agents, such as Revlimid® (lenalidomide) and Pomalyst® (pomalidomide)
- Proteasome inhibitors (PIs), such as Velcade® (bortezomib) and Kyprolis® (carfilzomib)
- Histone deacetylase (HDAC) inhibitor Farydak® (panobinostat)
- Monoclonal antibodies, such as DARZALEX®
- Corticosteroids, such as dexamethasone and prednisone
Other Multiple Myeloma Therapies
- Stem cell transplant
It is important to discuss your treatment options with your healthcare provider. Here is a list of questions to ask your healthcare provider.
For most people, treating multiple myeloma is an ongoing process due to the potential for disease recurrence or resistance to treatment. When your multiple myeloma relapses, you and your healthcare provider may want to discuss additional treatment options.
DARZALEX® is a prescription medicine used to treat a type of cancer called multiple myeloma in people who:
- Have received at least 3 prior medicines to treat multiple myeloma, including a proteasome inhibitor (PI) and an immunomodulatory agent, or
- Did not respond to a proteasome inhibitor (PI) and an immunomodulatory agent
It is not known if DARZALEX® is safe and effective in children.
DARZALEX® is approved based on response. Clinical trials are still ongoing.
DARZALEX® is the first monoclonal antibody approved for people with this type of cancer.
A monoclonal antibody is a man-made molecule that binds to substances in the body, including cancer cells. Monoclonal antibodies work with your immune system.
Revlimid® and Pomalyst® are registered trademarks of Celgene Corporation. Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc. Farydak® is a registered trademark of Novartis Pharmaceuticals Corporation. Kyprolis® is a registered trademark of Onyx Pharmaceuticals, Inc.